E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Heparin induced thrombocytopenia (HIT) Type II |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10048672 |
E.1.2 | Term | Heparin-induced thrombocytopenia type II |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To collect data on the clinical management of argatroban in subjects with heparin induced thrombocytopenia Type II who require parenteral antithrombotic therapy in France.
The population is most likely to include patients with suspected or confirmed heparin-induced thrombocytopenia Type II in whom the treating physician considers therapy with argatroban to be optimal including but not limited to those subjects with: - renal impairment with or without mild to moderate hepatic impairment - patients over 65 years of age - patients who cannot receive danaparoid or lepirudin - controllable haemorrhagic risk and mild moderate or severe renal impairment
|
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subjects aged ≥ 18 years
2. Females of child bearing potential must have a negative urine pregnancy test prior to entry into the study
3. Patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or without ongoing thrombosis who require parenteral anticoagulation
4. Signed written informed consent by the subject, or if the subject is unable to do so, consent will be sought from their family member, or a trusted person nominated by the subject or the legal representative
|
|
E.4 | Principal exclusion criteria |
1. Uncontrolled bleeding 2. Severe hepatic impairment (Child-Pugh Class C) 3. Hypersensitivity to argatroban or to any of the excipients (sorbitol and ethanol) 4. Pregnancy (exclusion by routine urine test) 5. Lactating woman
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Clinical Evaluations: - composite of all-cause death, thrombosis (new and extended) and unplanned amputation - all-cause death - death related to HIT - thrombosis (new and extended) - unplanned amputation - major / minor bleeding
Laboratory Evaluations: - platelet counts (recovery – speed and extent) - aPTT, ECT and TT (onset and maintenance) - D-dimer, Thrombin generation Test (TGT), Prothrombin Fragnment F1.2 and microparticles - plasma concentration of argatroban in relation to aPTT, ECT and TT
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 0 |